SIGA Technologies All Financial Data in US $ (mln)
Worldwide
 
Overview
 


EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile SIGA Technologies (SIGAQ) is a New York based pharmaceutical company focused on development of therapeutic solutions for some of the most lethal disease causing pathogens including Ebola & other dangerous viruses.

13 APR 2016: U.S. Bankruptcy Court of New York approved a reorganization plan under which SIGA Technologies will exit from bankruptcy w.e.f. 12 APR 2016.
Listed or Private Company Listed
Company Classification Biotechnology
Country USA
Company Website Website
Technology Platform Profile

EvaluatePharma® Coverage of Marketed and Pipeline Products

Product Count
SIGA Technologies
   R&D 10
   Suspended in R&D 1
   Abandoned in R&D 10
   Disposed in R&D 1
  Total (SIGA Technologies)1 22

Financial Analysis

SIGA Technologies Data Growth
2014 2015 2015
  Valuation Measures
   Based on Period End Share Prices
      Valuing the Equity
       PE Ratio (diluted) - Normalised (x) (0.6) (1.3) 106.4%
  Forecast Financials
   Income Statement
     Total Revenues 3 8 160%
     S,G & A (13) (11) (16%)
     R&D (11) (13) 21%
     Other Income/ Expense - Net (1)2 (1)3 2%
     EBIT - Normalised (21) (17) (22%)
     Net Interest & Financial Items (0) (0) 59%
     Pre-tax Profits - Normalised (21) (17) (21%)
     Exceptionals (191)4 (22)5 (88%)
     Income Before Taxes (212) (39) (82%)
     Tax (54) (0) (99%)
     Tax Rate (%) 25.3% 1.2% (95.3%)
     Net Income - Reported (265)6 (39)7 (85%)
     Net Income - Normalised8 (123)9 (17)10 (86%)
   Per Share Data
     EPS - Diluted (4.97) (0.73) (85.24%)
     EPS - Basic (4.97) (0.73) (85.24%)
     EPS - Normalised (diluted)11 (2.30) (0.33) (85.87%)
     EPS - Normalised (basic) (2.30) (0.33) (85.87%)
     Avg. Shares Outstanding - Diluted 53.4 53.8 0.7%
     Avg. Shares Outstanding - Basic 53.4 53.8 0.7%
     DPS 0.00 0.00 0.00%

Share Price Details

2016
SIGA Technologies
 Ticker SIGA
 Exchange OOTC (OTHER OTC)
 Share Price (Closing) 2.99
 Share Price Date 30/09/2016

Market Valuation

2016
SIGA Technologies
 Market Cap 162
 Cash 113
 Debt 0
 Enterprise Value 50

Note: Daily share prices and certain other per-share data are supplied to EvaluatePharma Ltd by a third party and under the terms of supply are available for on-screen viewing purposes only. Copying these data out of EvaluatePharma is not permitted and such data are masked within downloads into Excel (TM).


Welcome

Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


Partnering

EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.


Register to access more FREE content:

  • 2011 Product Sales analysis
  • 2011 Pharmaceutical Sales
  • 2011 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now